^
Association details:
| Biomarker: | ROS1 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy of tyrosine kinase inhibitors in patients with non-small-cell lung cancer with performance status 4: a case series and review of the literature
Published date:
09/28/2023
Excerpt:
A 50-year-old Japanese man presented with symptoms of chronic cough and dyspnea and was diagnosed with stage IV NSCLC in October 2020….Genotype testing revealed an ROS1 mutation; therefore, the patient was administered crizotinib (500 mg) daily...Crizotinib was discontinued until hepatotoxicity improved and, then, restarted at a reduced dose (400 mg) daily. A significant improvement in PS was noted within 2 weeks, with PS changing to 1. He underwent an initial evaluation of the therapeutic effects by CT scan on day 21 of the treatment. Significant shrinkage of the primary tumor and metastasis was detected...
DOI:
https://doi.org/10.1186/s13256-023-04145-z
